Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical study on cefprozil in pediatrics].

N Iwai1, M Miyazu, H Nakamura

  • 1Department of Pediatrics, Meitetsu Hospital.

The Japanese Journal of Antibiotics
|November 1, 1992
PubMed
Summary

Cefprozil (CFPZ) demonstrated high clinical and bacteriological effectiveness in pediatric infections, with a 96.4% overall efficacy rate. This oral cephalosporin showed excellent safety, with no observed side effects in children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Semidiscoid lateral meniscus].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

[Abnormal chest shadow on CT in immunosuppressed patients].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

[MR imaging evaluation of plica synoviallis mediopatellaris of the knee joint].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

Structure-activity relationships of mu-conotoxin GIIIA: structure determination of active and inactive sodium channel blocker peptides by NMR and simulated annealing calculations.

Biochemistry·1992
Same author

Tumor necrosis factor modulation of expression of the cystic fibrosis transmembrane conductance regulator gene.

FEBS letters·1992
Same author

Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments.

FEBS letters·1992

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacology
  • Clinical Microbiology

Background:

  • Cefprozil (CFPZ) is a novel oral cephalosporin evaluated for pediatric use.
  • Assessing clinical efficacy, bacteriological outcomes, and safety is crucial for new antibiotics.

Observation:

  • A study involved 116 pediatric patients aged 4 months to 11 years with various infections.
  • Cefprozil was administered at 4.6-14.1 mg/kg daily for 3-10 days.
  • Clinical and bacteriological data were collected from 112 patients.

Findings:

  • Cefprozil achieved a 96.4% clinical effectiveness rate across infections like pharyngitis, tonsillitis, pneumonia, and UTI.
  • Bacteriological eradication rates were 97.1% for Gram-positive and 56.8% for Gram-negative bacteria.
  • No significant side effects or ingestion refusal were noted; minor laboratory abnormalities were rare.

Implications:

  • Cefprozil is a safe and highly effective antibiotic for treating common pediatric infections.
  • Its favorable safety profile and efficacy support its use in pediatric clinical practice.
  • Further research may explore its role against resistant bacterial strains.

Related Experiment Videos